Zhixiang Jintai announced that recently, the company submitted a new drug marketing application to the Drug Evaluation Center of the State Drug Administration for the indication of telicibimab injection for moderate and severe atopic dermatitis in adults and was accepted. Telicibimab injection is a recombinant all-human anti-IL-4Rα monoclonal antibody independently developed by the company. The target of action is IL-4Rα.

Zhixiang Jintai announced that recently, the company submitted a new drug marketing application to the Drug Evaluation Center of the State Drug Administration for the indication of telicibimab injection for moderate and severe atopic dermatitis in adults and was accepted. Telicibimab injection is a recombinant all-human anti-IL-4Rα monoclonal antibody independently developed by the company. The target of action is IL-4Rα.